Business
Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Webinar to be held on Thursday, December 16, 2021, at 2:30 p.m. ET WORCESTER, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:
About this update from Mustang Bio, Inc.
[{"type":"text","content":"Webinar to be held on Thursday, December 16, 2021, at 2:30 p.m. ET WORCESTER, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it will host a key opinion leader (“KOL”) webinar on MB-106, the Company’s CD20-targeted, autologous CAR T cell therapy for the treatment of B-cell non-Hodgkin lymphomas (“B-NHLs”) and chronic lymphocytic leukemia (“CLL”), on Thursday, December 16, 2021, at 2:30 p.m. Eastern Time. The webinar will feature a presentation by Mazyar Shadman, M.D., M.P.H., Associate Professor at the Fred Hutchinson Cancer Research Center (“Fred Hutch”) and a physician at Seattle Cancer Care Alliance, who will discuss updated interim results from the ongoing Phase 1/2 clinical trial investigating the safety and efficacy of MB-106 for patients with relapsed or refractory B-NHLs and CLL. These data were selected for presentation at the the 63rd American Society of Hematology Annual Meeting (“ASH2021”), which is being held December 11-14, 2021. Dr. Shadman, along with colleague Brian Till, M.D., also an Associate Professor at Fred Hutch and physician at Seattle Cancer Care Alliance, will be available to answer questions following the formal presentations. Mustang Bio’s management team will provide additional details on the planned MB-106 Phase 1/2 clinical trial to be conducted under Mustang’s Investigational New Drug (“IND”) application. The U.S. Food and Drug Administration accepted Mustang’s IND to initiate a multicenter Phase 1/2 clinical trial investigating the safety, tolerability and efficacy of MB-106 for relapsed or refractory B-NHLs and CLL. To register for the event, please click here. About Dr. ShadmanMazyar Shadman, M.D., M.P.H., is an Associate Professor at the University of Washington (“UW”) and Fred Hutch as well as a physician at Seattle Cancer Care Alliance. He is a hematologic malignancies expert who specializes in treating patients with lymphoma and CLL. Dr. Shadman is involved in clinical trials using novel therapeutic agents, immunotherapy (CAR T cells), and stem cell transplant for treatment of lymphoid malignancies with a focus on CLL. He als...